Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Not yet recruiting Not applicable Interventional

Clinical Outcomes of Root Canal Treatment Using Modern Irrigation Protocols

NCT07852312
View directory record Official record
Conditions
Pulp Disease, Dental
Interventions
GentleWave®, EdgePRO™, Fotona LightWalker®, Conventional Needle Irrigation
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers

NCT02457806
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo spray
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

NCT01076049
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Abscess
Interventions
Standard of Care (SoC), Irrisept Delivery System
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

From Innovation to Solutions: Childhood Influenza Vaccination Planning

NCT01664793
View directory record Official record
Conditions
Influenza
Interventions
4 Pillars Immunization Toolkit
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 18 Years
Enrollment
87,665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Comparison of Methods for the Delivery of Interoceptive Exposure

NCT01201304
View directory record Official record
Conditions
Anxiety Sensitivity
Interventions
Standard exposure, Enhanced exposure, Intensive exposure, Expressive writing
Behavioral
Lead sponsor
University of Wyoming
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 22, 2026, 5:10 AM EDT
Withdrawn Phase 4 Interventional

Rescue Quadratus Lumborum Blocks for Post-cesarean Pain

NCT04397458
View directory record Official record
Conditions
Morphine, Analgesics, Analgesics, Opioid, Peripheral Nervous System Agents
Interventions
Saline, Bupivacaine, Dexamethasone
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

NCT04945707
View directory record Official record
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

NCT00333398
View directory record Official record
Conditions
Influenza
Interventions
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
10
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Early Phase 1 Interventional

NSAIDs Stent Study

NCT03638999
View directory record Official record
Conditions
Ureteral Stent Placement, Kidney Stone
Interventions
Ketorolac Trometamol 30Mg/1mL Injection, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers

NCT03905863
View directory record Official record
Conditions
Diabetic Foot Ulcer, Surgical Wound
Interventions
Natrox® Oxygen Wound Therapy
Device
Lead sponsor
Inotec AMD Limited
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 22, 2026, 5:10 AM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

NCT04075513
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed No phase listed Observational

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

NCT03831997
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Dextrose 5% W/ Sodium Chloride 0.225%
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

NCT01286168
View directory record Official record
Conditions
Nonmalignant Breast Conditions, Breast Cancer
Interventions
Sodium hypochlorite (Dakin's Solution), Chlorhexidine gluconate disk, Control, Occlusive Adhesive Dressing
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 22, 2026, 5:10 AM EDT